Abstract: The present invention relates to a fluidic intraocular lens inserted into a capsular bag of an eye to replace a crystalline lens. The fluidic intraocular lens may be shaped by elastic membranes bonded to a support ring. The space inside the device may be filled with optically transparent fluid or gel having an index of refraction greater than the index of vitreous humor. The device may be such designed so that the focusing power of the lens can be changed by the deformation of the capsular bag, which may be subsequently controlled by a ciliary muscle.

Abstract: The present invention relates to providing new vaccines and treatments for the diseases related to canine influenza virus. It discloses influenza viral antigens, and methods of presenting these antigens to canines, especially dogs. It relates to attenuated and killed vaccines. The present invention relates to experimentally generated canine and equine influenza viruses. invention also includes influenza A, including H3, N8, H3N8, H7N7 and viruses which contain at least one genome segment from an canine or equine influenza virus. The present invention also relates to the use of these viruses in therapeutic compositions to protect canines, dogs in particular, from diseases caused by influenza viruses.

Abstract: This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira Bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona. The vaccines of the present invention include a Bordetella bronchiseptica p68 antigen.

Abstract: The present invention relates to providing new vaccines and treatments for the diseases related to canine influenza virus. It discloses influenza viral antigens, and methods of presenting these antigens to canines, especially dogs. It relates to attenuated and killed vaccines. The present invention relates to experimentally generated canine and equine influenza viruses. The invention also includes influenza A, including H3, N8, H3N8, H7N7 and viruses which contain at least one genome segment from an canine or equine influenza virus. The present invention also relates to the use of these viruses in therapeutic compositions to protect canines, dogs in particular, from diseases caused by influenza viruses.

Abstract: In a computer-implemented method of determining an abstraction of a plurality of differentiated goods available for exchange, data regarding each differentiated good is stored in a computer storage, wherein the data regarding each differentiated good includes an attribute value assigned to at least one attribute of the differentiated good. A processor of a computer determines a first abstraction of the plurality of differentiated goods based on the stored data. The first abstraction includes at least one abstract good. Each abstract good includes one or more differentiated goods. At least one abstract good of the first abstraction includes at least two distinct differentiated goods. The processor determines for each abstract good a specification for the abstract good based on the data regarding one or more differentiated goods forming the abstract good. The processor stores in the computer storage the specification determined for each abstract good.

Abstract: The present application describes antibodies that selectively bind human Fc?RIIB, with little or no binding to other human Fc?Rs, e.g., human Fc?RIIA. The invention also provides isolated bispecific antibodies comprising an antibody that selectively binds Fc?RIIB, and a second antibody that specifically binds an activating receptor. Various uses, including therapeutic uses, for those antibodies are also described, including administration with anti-tumor antibodies and methods of inhibiting immune responses and suppressing histamine release.

Abstract: The present application describes antibodies that selectively bind human Fc?RIIB, with little or no binding to other human Fc?Rs, e.g., human Fc?RIIA. The invention also provides isolated bispecific antibodies comprising an antibody that selectively binds Fc?RIIB, and a second antibody that specifically binds an activating receptor. Various uses, including therapeutic uses, for those antibodies are also described, including administration with anti-tumor antibodies and methods of inhibiting immune responses and suppressing histamine release.

Abstract: In a combinatorial exchange, rules can be input for processing bids and a desired exchange objective can be defined. A subset of the rules can be used to determine if an allocation of the bids exists that is optimal for the type of exchange being conducted. If the desired exchange objective is not satisfied, new allocations can be determined using different subsets of rules each time until the desired exchange objective is satisfied. At least one of the bids can include a reference ratio; a discount; a price associated with a quantity Q1 of a first item; a price associated with a quantity Q2 of a second item; and a rule that causes said discount to be applied to an average price of Q1 and an average price of Q2 for each instance of the allocated quantity Q1 over the allocated quantity Q2 that equals the reference ratio.

Abstract: In a combinatorial exchange, a set of rules can be input for processing of bids received in connection with the exchange. At least one bid can be received from each of a plurality of exchange participants and a desired exchange objective can be defined. A determination can be made as a function of a subset of the rules if an allocation of the bids exists that is optimal for the type of exchange being conducted. If the desired exchange objective is not satisfied, the step of determining an allocation is repeated utilizing a different subset of rules each time until the desired exchange objective is satisfied. It can be determined if the exchange is overconstrained and, if so, rules can be relaxed. Also or alternatively, the demand for a quantity of an item can be increased or decreased based on the average cost of the item.

Abstract: In a combinatorial exchange, rules can be input for processing bids and a desired exchange objective can be defined. A subset of the rules can be used to determine if an allocation of the bids exists that is optimal for the type of exchange being conducted. If the desired exchange objective is not satisfied, new allocations can be determined using different subsets of rules each time until the desired exchange objective is satisfied. Trigger bid groups and/or rules associated with trigger values can be used to determine whether to apply modification or discounts to bids. Item and bid groups can be partitioned into groups for the purpose of smoothing requirements. Trigger bid groups, rules associated with trigger values, item groups, and bid groups can be used for adjusting or constraining bids based on triggers, logical connectives, and adjustments.

Abstract: In a combinatorial exchange, a set of rules can be input for processing of bids received in connection with the exchange. At least one bid can be received from each of a plurality of exchange participants and a desired exchange objective can be defined. A determination can be made as a function of a subset of the rules if an allocation of the bids exists that is optimal for the type of exchange being conducted. If the desired exchange objective is not satisfied, the step of determining an allocation is repeated utilizing a different subset of rules each time until the desired exchange objective is satisfied.

Abstract: The present application describes antibodies that selectively bind human Fc?RIIB, with little or no binding to other human Fc?Rs, e.g., human Fc?RIIA. The invention also provides isolated bispecific antibodies comprising an antibody that selectively binds Fc?RIIB, and a second antibody that specifically binds an activating receptor. Various uses, including therapeutic uses, for those antibodies are also described, including administration with anti-tumor antibodies and methods of inhibiting immune responses and suppressing histamine release.

Abstract: In a live, expressive combinatorial exchange, each of a plurality of bidders can submit a bid. Based on the submitted bids, an allocation of the bids is determined that is optimal for the type of exchange being conducted. At least a portion of each bid of the allocation is displayed to each bidder of a first subset of the bidders that has at least one bid that is not included in the allocation. Each bidder of a subset of the first subset of bidders can then amend one or more of their existing bids or submit a new bid that is considered the next time the allocation is determined. The process of feeding back at least a portion of each bid of the allocation, submitting new bids or amendments to existing bids, and determining a new allocation based on all of the submitted bids continues until a predetermined condition is satisfied.

Abstract: The present invention relates to providing new vaccines and treatments for the diseases related to canine influenza virus. It discloses influenza viral antigens, and methods of presenting these antigens to canines, especially dogs. It relates to attenuated and killed vaccines. The present invention relates to experimentally generated canine and equine influenza viruses. invention also includes influenza A, including H3, N8, H3N8, H7N7 and viruses which contain at least one genome segment from an canine or equine influenza virus. The present invention also relates to the use of these viruses in therapeutic compositions to protect canines, dogs in particular, from diseases caused by influenza viruses.

Abstract: This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira Bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona. The vaccines of the present invention include a Bordetella bronchiseptica p68 antigen.

Abstract: A desirable allocation of bids in a combinatorial exchange can be selected by determining a first candidate allocation of the bids and a first value of a minimax regret, related to the difference in utility between the adversarial allocation and the candidate allocation, as a function of a first adversarial allocation of the bids. Based on the first candidate allocation, a second adversarial allocation of the bids and a first value of a maximum regret related to the difference in utility between the new adversarial allocation and the utility of the candidate allocation can be determined. When the value of the maximum regret is greater than the value of the minimax regret, the candidate allocation can be designated as the desirable allocation.

Abstract: A body bed is provided for use by pregnant women and other persons for sleeping on their stomachs. A mattress includes a tummy well formed in the central region thereof and a tummy well strap including VELCRO attached to both ends of the strap. The bottom surface of the mattress has VELCRO material so that the tummy well strap may be continuously adjusted to any length to provide optimum support for the spine of the user. The mattress may also include a separate breast well and a separate breast well strap having VELCRO ends which may be continuously adjusted to any length to provide optimum support for the spine of the user.

Abstract: A wheat variety designated XW02M, the plants and seeds of wheat variety XW02M, methods for producing a wheat plant produced by crossing the variety XW02M with another wheat plant, and hybrid wheat seeds and plants produced by crossing the variety XW02M with another wheat line or plant, and the creation of variants by mutagenesis or transformation of variety XW02M. This invention also relates to methods for producing other wheat varieties or breeding lines derived from wheat variety XW02M and to wheat varieties or breeding lines produced by those methods.

Abstract: A wheat variety designated XW02M, the plants and seeds of wheat variety XW02M, methods for producing a wheat plant produced by crossing the variety XW02M with another wheat plant, and hybrid wheat seeds and plants produced by crossing the variety XW02M with another wheat line or plant, and the creation of variants by mutagenesis or transformation of variety XW02M. This invention also relates to methods for producing other wheat varieties or breeding lines derived from wheat variety XW02M and to wheat varieties or breeding lines produced by those methods.

Abstract: This invention relates to vaccines and methods for protecting dogs against disease caused by Bordetella bronchiseptica. This invention also relates to combination vaccines and methods for protecting dogs against disease or disorder caused by canine pathogens, for example, infectious tracheobronchitis caused by Bordetella bronchiseptica, canine distemper caused by canine distemper (CD) virus, infectious canine hepatitis (ICH) caused by canine adenovirus type 1 (CAV-1), respiratory disease caused by canine adenovirus type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza (CPI) virus, enteritis caused by canine coronavirus (CCV) and canine parvovirus (CPV), and leptospirosis caused by Leptospira Bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae or Leptospira pomona. The vaccines of the present invention include a Bordetella bronchiseptica p68 antigen.